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Summary 
The human Fc3,RI (CD64) is a high a~nity receptor for the Fc portion of immunoglobulin 
(Ig),  and its constitutively low expression  on the cell surface of monocyte/macrophage and 
neutrophils is selectively  upregulated by interferon 3' (IFN-3') treatment (Perussia, B., E. T. Dayton, 
R. Lazarus, V. Fanning, and G. Trinchieri. 1983.J. Extx Med. 158:1092). Three distinct cDNAs 
have been cloned and code for proteins that predict three extraceUular Ig-like domains (Allen, 
J. M., and B. Seed. 1989. Science [Wash. DC]. 243:378).  Several differences in the coding region 
of these cDNAs suggest that in addition to polymorphic differences a second Fc3,RI gene could 
possibly exist. This alternative Fc3,RI gene (Fc3,RIb) was defined by the lack ofa genomic HindlII 
restriction site (van der Winkel, J. G. J., L. U. Ernst, C. L. Anderson, and I. M. Chiu. 1991. 
J. Biol. Chem.  266:13449).  We describe the characterization a second gene (Fc3,RIb)  that has 
a termination codon in the third extracellular  domain and therefore predicts a soluble form of 
the receptor.  We also define two distinct IFN-3'-responsive  regions in the 5' flanking sequence 
of Fc3,RIb that resemble motifs that have been defined in the class II major histocompatibility 
complex promoter. The Fc3,RIb promoter does not possess canonical TATA or CCAAT boxes, 
but does possess a palindromic motif that closely resembles the initiator sequence identified in 
the terminal deoxynucleotidyl transferase/human leukocyte IFN/adeno-associated virus type II 
P5 gene promoters (Smale, S. T., and D. Baltimore. 1989. Cell. 57:103; Seto, E., Y. Shi, and 
T. Shenk. 1991. Nature [Lond.]. 354:241; Roy, A. L., M. Meisterernst, P. Pognonec, and R. C. 
Koeder. 1991. Nature[Lond.]. 354:245) virus type II P5 gene promoters raising interesting questions 
as to its role in the basal and myeloid-specific transcription of this gene. 
T 
reatment of mammalian cells with species specific IFNs 
(c~, ~, and 3,) induces shared and distinct cellular responses 
that result from induction or repression of selected genes (1). 
IFN-ol  and -~  are products of all cells,  share  a common 
receptor, and exert similar effects on cells. IFN-3,, a product 
of activated T cells and NK cells, has a distinct cell surface 
receptor and induces unique effects as well as responses shared 
with IFN-ol and -~/(reviewed in reference 2). In vitro and 
in vivo administration of IFN-3, indicates that its predomi- 
nant physiological role is to modulate immune functions. In 
particular,  IFN-3,, but not IFN-or and -B, induces monocyte 
differentiation, and IFN-3, is the predominant macrophage- 
activating factor (3, 4). As such, myeloid cells must have sets 
of genes whose expression is regulated in response to IFN-3, 
treatment. The net effect of these IFN-3,-dependent pleio- 
typic changes is that the treated phagocytes display an acti- 
vated phenotype (5). Macrophages activated by IFN-y treat- 
ment  downregulate  mannose  receptors  and  collagenase 
secretion,  and upregulate expression of components of the 
NADPH oxidase, IL-1, I1,-8, TNF, IP10, monokine induced 
by IFN-3, (MIG), 1 the MHC class I and II antigens, and Fc 
receptors (6-13). 
Responses of genes that are regulated by IFN-ct/~ appear 
to  be  mediated by  a  conserved motif,  termed  the  IFN- 
stimulated response element (ISRE),  located within their 
regulatory regions (1, 4, 14, 15). Interestingly, transcriptional 
upregulation of genes containing the ISRE by IFN-ol/B are 
augmented by IFN-3,.  ISGF3 is a positive multimeric trans- 
activating factor that targets the ISRE by translocating inde- 
pendent subunits from the cytoplasm to the nucleus upon 
IFN-c~ treatment. One component, ISGP33,, appears essen- 
1 Abbreviations  used in this  paper: ISRE, IFN-stimulated response element; 
MIG, monokine induced  by IFN-y. 
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Volume  176  October 1992  1115-1123 tial for DNA binding and its synthesis is upregulated after 
treatment with IFN-3' (16).  Although less well character- 
ized, a similar complex interaction between multiple factors 
is likely to account for the transcriptional control of genes 
that are exclusively upregulated by IFN-3,. The best studied 
of these genes are the MHC class II genes whose promoters 
contain a series of conserved c/s-acting elements termed X, 
Y, and H box and IFN-3' response element (3,-IRE) (reviewed 
in reference 17). A number of independent studies indicate 
that IFN-y responsiveness  of this region cannot be accounted 
for by a DNA binding protein with one precise element. Our 
focus is to examine the regions that determine IFN-3' respon- 
siveness in the context of a myeloid cell so as to gain insight 
into the molecular mechanisms that underlie the role of IFN-3, 
as a macrophage-activating factor. To this end, the regula- 
tion of the human Fc3~R.I gene is an attractive candidate as 
its expression is restricted to myeloid cells and is specifically 
upregulated by IFN-%  IFN-y treatment alone results in a 
rapid increase in transcription of the Fc',/RI gene that results 
in up to a 20-fold induction of mRNA levels and expression 
of hundreds of thousands of cell surface receptors (reviewed 
in reference 18). The study of the regulation of the Fc"/RI 
gene should therefore provide insights into defining c/s-acting 
elements that confer myeloid specificity as well as definition 
of enhancers that target selective induction by IFN-3'. 
Fc~RI is a member of a family of membrane receptors that 
recognize the Fc domain of Ig. The characterization of Fc 
receptors by molecular cloning has detailed a complex family 
of molecules that have a wide cellular distribution and a con- 
siderable structural heterogeneity that defines the diverse cel- 
lular responses triggered by ligation of Fc receptors (18). Fc3,RI 
has  a third Ig-like intracellular domain that determines its 
unique ability among Fc receptors to bind the monomeric 
Ig, and hence its designation as a high affinity Fc receptor, 
Three distinct cDNAs predict almost identical glycoproteins 
in their extracellular and transmembrane regions but differ 
in their cytoplasmic tails  (19).  Recent reports have detailed 
the genomic organization of the FcyRI gene (20,  21) and 
provided evidence to support the existence of a second gene 
as defined by a difference in a HindIII restriction fragment 
length (20). 
In this study we provide a detailed analysis of the genomic 
organization of the putative second Fc'yRI gene (FcyRIb), 
which lacks HindlII in the second intron site due to a point 
mutation. In addition, a termination codon in the third ex- 
tracellular domain and an insertion of a single amino acid 
appear to be the major points that distinguish this as a second 
gene. We have also mapped the regions in the Fc3rRI pro- 
moter that confer IFN-~/responsiveness  and myeloid specificity. 
The c/s-acting  dements share some homology with defined 
IFN-3, dements found in MHC class II promoters as well 
as having unique properties. 
Materials and Methods 
Cells and Cell Cultures.  U937, THP-1, Raw 264.7, and Hela 
cells were obtained from the American Type Culture Collection 
(RockviUe, MD) and were maintained in RPMI supplemented with 
10% FCS, 2 mM t-glutamine,  1 mM sodium pyruvate, and gen- 
tamycin (complete medium). All media and tissue cultures were 
scrupulously monitored  to ensure endotoxin-free conditions. 
Isolation of tke 5' Flanking Region of the Fc~RI Gene.  A human 
genomic library was screened by plaque hybridization using the 
5' portion of Fc3'RI cDNA (-27 to  +157; numbering from the 
ATG) as the probe. After prehybridization in 6 x  SSC, 5 x  Den- 
hardt's, 0.1% SDS for 2 h at 68~  the random primed labeled 
probe (100,000  cpm/ml) was added and hybridization  was performed 
at the same temperature for 12 h. Filters were washed serially in 
2x  SSC, 0.1% SDS for 30 min at 68~  with 0.2x  SSC, 0.1% 
SDS for an additional 30 min at 68~  and with 0.2x SSC, 0.1% 
SDS for an additional 30 min at 68~  followed by autoradiog- 
raphy for 12 h. Positive plaques were picked and rescreened for an 
additional two rounds, after which DNA of the positive phages 
was prepared, restriction digested, and analyzed on Southern blot 
prehybridized in 6x SSC, 1 x  Denhardt's, 0.5% SDS, 0.05% so- 
dium pyrophosphate at 37~  for 1 h and hybridized at the same 
temperature for 12 h in the same solution containing  106 cpm/ml 
of  a 5' end-labeled  oligonucleotide primer (-7 to -26; representing 
the 5' end of the cDNA). 
Plasmid Construction.  The PEcoR143 vector was created by sub- 
cloning the 4.3-kb EcoRI genomic fragment,  representing the 5' 
exon and the 5' flanking region, into the EcoRI site ofpUC9 vector. 
For the SV40 heterologous promoter CAT constructs, PEcoR143 
was used as template to generate fragments synthesized by the PCR 
from appropriate oligonucleotide primers, to which were added 
sequences for BgllI restriction endonucleases. The amplified frag- 
ment was then cloned into the BgllI site of the reporter plasmid 
pCAT (Promega Biotec, Madison, WI), which contains the bac- 
terial chlorophenicol acetyl transferase reporter gene downstream 
of the SV40 basal promoter element. 
Construca'on of the  TKCAT and Promoterless CAT Constructs. 
PEcoR143 was used as a template to generate progressively deleted 
fragments of the 5' flanking region spanning  -242 to  -5 by the 
PCR using  the following primers:  (a)  NotI-FcPCRSb  (189 to 
-160)  +  Xba-FcPCR3 (-28 to  -7)  =  -189 to  -7; (b) NotI- 
FcPCR5c (- 128 to - 99) + XbaI- FcPCR3 (- 28 to - 7) =  - 128 
to -7; (c) NotI-FcPCR5d (-78 to -49)  +  XbaI-FcPCR3 (-28 
to  - 7)  =  - 78 to  - 7; (aT) NotI-FcPCR5b (- 189 to  - 160)  + 
XbaI-GRR2 (- 154 to - 119) =  - 189 to - 119; (e) BamHI-GRRa 
(- 169 to  - 141)  +  BamHI-GKRb (- 158 to  - 128)  =  - 169 to 
-128; (J) NotI-FcPCR5c  (128 to  -99)  +  XbaI-gI-PCR1  (-102 
to - 74)  =  - 128 to - 74; (g) BamHI-GRRa (- 169 to  - 141) + 
XbaI-GRR2 (- 159 to  - 119)  =  - 169 to  - 119. 
The fragments generated in reactions a-d were ligated into the 
Nod and Xbal sites of pBRAMS cat1 (22) to generate CAT con- 
structs in which the CAT gene is under control of the endogenous 
CD64 5' flanking region promoter (see Fig. 5 B). 
Fragments generated in reactions d-h were ligated into either 
NotI/XbaI, BamHI, or NotI (blunted)/XbaI  (in the case of"h') 
sites upstream of the TK promoter in the vector pBRAMS cat2. 
Cell Transfection.  U937 or THP-1 cells were grown as suspen- 
sion cultures in 250-ml flasks. 5  x  106 cells were transfected with 
20/xg of DNA using the DEAE-dextran method (23). Briefly, 40 
/~g DNA was combined with 400/zg/ml of DEAE-dextran in a 
final volume of I ml of media containing 10% Nu-Serum. After 
5 min at room temperature, the mixture was added to a 1-ml cell 
suspension (107 ceUs/ml) in media containing 10% Nu-Serum and 
incubated  for 2 h  at  37~  5%  CO2-air. The cells were then 
washed once in Dulbecco's PBS and shocked for 3 min in 10% 
DMSO in HBSS (5 mM KC1, 0.4 mM KH2PO4, 140 mM NaC1, 
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37~  The DMSO was then diluted by addition of excess medium 
to the cells, washed twice with PBS followed by resuspension in 
20 ml complete medium,  and divided into two equal aliquots of 
10 ml each. Each aliquot was then grown for 48 h at 37~ 
CO2-air before induction of one aliquot with 300 U/ml of recom- 
binant human IFN-~/at 37~  for 12 h. The other aliquot served 
as the noninduced  control. 
Hela  and  RAW  264.7 cells were plated  at  a density  of 106 
cells/100-mm petri dish on the evening before the day of transfec- 
tion. The following morning each 100-ram dish was washed twice 
with PBS. Each dish was then incubated with a mixture of 20/zg 
DNA, 200/~g/ml DEAE-dextran in a final volume of 3.5 ml of 
RPM11640 containing 10% Nu-Serum. The dishes were incubated 
for 2-4 h  at  37~  COrair.  The monolayers were washed 
once with PBS and shocked for 3 rain at 37~  with 3 ml of 10% 
DMSO in HBSS. The DMSO was then diluted by an addition of 
excess medium to the cells, washed gently once with PBS, followed 
by an addition of excess medium to the cells, washed gently once 
with PBS, followed by an addition of 10 ml complete medium. 
The dishes were incubated overnight at 37~  CO2-air. Each 
dish was then split by limited trypsin-EDTA treatment and replated 
in two equal aliquots in 60-mm dishes and reincubated for an addi- 
tional 24 h before stimulation of one subset with 300-400 U/ml 
of recombinant human or murine IFN-3~ for 12 h at 37~  The 
other subset served as the noninduced control. 
CAT Assays.  Cells  were harvested and CAT assays were per- 
formed as follows. Adherent cells were washed three times with 
PBS and then incubated 5 rain at room temperature  in I  ml of 
TEN buffer (40 mM Tris-HC1 pH 7.5,  1 mM EDTA, 15 mM 
NAC1). The cells were then scraped off with a rubber policeman, 
and the suspension was spun in an Eppendorf microfuge for 10 
rain at 4~  at 14,000 rpm. The cell pellet was resuspended in 150 
/~1 of 0.2 M Tris-HC1, pH 8, and subjected to three freeze-thaw 
cycles with vortexing after each thaw cycle. After heating at 60~ 
for 10 min, the extract was spun for 10 min at 4~  and the super- 
natant was transferred to a fresh tube. CAT activity was performed 
on 50/zl of the other by extraction, using n-butyryl coenzyme and 
xylene extraction  as described in the CAT enzyme assay system 
protocol  of Promega  Biotech  followed by  liquid  scintillation 
counting or by separation on TLC. Activities were adjusted for 
differences  in the protein concentration of the extracts. Nonadherent 
cells were washed three  times in PBS. The cell pellet was then 
resuspended in 1 ml of TEN buffer and the suspension was trans- 
ferred to a microfuge tube and incubated at room temperature for 
5 rain. The subsequent steps were the same as for adherent cells. 
Results 
FcTRIb Gene.  While considerable structural differences 
characterized  Fc~RII  and  Fc3rRIII  gene  families,  Fc'yRI 
(CD64) has been considered a product of a single gene though 
three distinct cDNAs had been described. We isolated genomic 
clones by using a radiolabeled Fe~tLI eDNA (p130) as a probe. 
The genomic structure indicates six exons (Fig. 1) that pre- 
dict a polypeptide that differs from the predicted products 
indicated by the three published Fc~RI cDNAs. Although 
each extracellular (EC) domain is encoded by a distinct exon, 
as would be predicted for members of the Ig superfamily, 
there is a termination codon at bp705 in EC domain 3 that 
would predict a soluble form of the receptor. We have also 
noted that at bp565, nucleotide TG does not appear in the 
cDNAs but is replaced by a 6-bp ACAATA sequence in the 
genomic done. The net result is that the gene sequence predicts 
an extra in-flame amino acid, Gln. Further differences in the 
genomic sequence of Fc~tLI and Fc3,RIb are reflected at 6 bp 
within the 5' boundary of the fifth intron, as underlined in 
Table 1, and several point mutations that are highlighted in 
Table 2.  The entire gene is interrupted by five introns that 
demarcate six exons (shown in Fig. 1 and Table 1). The first 
exon begins at the transcription initiation sites (see below) 
and encompasses the translation start site and "he putative 
signal peptide. Next is a small 21-bp exon followed by three 
extracellular Ig domain exons. The 3' UT region is encoded 
by the sixth exon. 
The p98/X2 eDNA predicts a polypeptide that has a shorter 
cytoplasmic tail with a divergent sequence. We have been un- 
able to identify the exon(s) coding for this divergent sequence. 
It is possible that this variant form could arise as a result of 
alternative splicing and that a further 3' exon(s) encodes the 
12 divergent amino acids present in the shorter cytoplasmic 
tail of clone p98/X2. 
The FcyRI Upstream Regulatory Region.  We next set out 
to determine whether Fc'yRI mRNA was upregulated as a 
specific response to IFN-'y treatment (reviewed in reference 
18).  Fig.  3  a  shows  that  overnight treatment  of the my- 
domonocytic cell line U937 with  IFN-'y but  not  IFN-ct 
resulted in an induction of two distinct mRNAs  of ~ol.7 
and ,'ol.2 kb, respectively. It seems likely these mRNAs rep- 
+1 
I 
ATG 
128 bp  21 bp  254 bp  252 bp 
EC1  EC2 
Approx.  8.0  kb 
285 bp 
EC3 
431 bp 
Figure 1.  Human  Fc~KIb genomic  organization. 
Open boxes represent  untranslated regions of exons; 
failed  area  represent  coding  region.  The numbers  above 
the boxes  indicate  the size  of  exons,  while  those  below 
indicate the size  ofintrons.  Ec, external  domain; CYT, 
cytoplasmic tail. 
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Intron  5 ~ boundary  Intron length  3' boundary 
kb 
67  68 
I  CTC  CTT  TGG G  gtaagttggact .........  ~0.45  ......... gatctcttgcag  TT  CCA GTT  GAT 
Leu  Leu  Trp  V  al  Pro  Val  Asp 
88  89 
II  GGG CAA GTG  G  gtgagtgatctc .........  ~0.85  ..........  atctccaagtag  AC ACC ACA AAA 
Gly  Gin  Val  A  sp  Thr  Thr  Lys 
343  344 
III  ATC  CAC AGA G  gtaattatgact .........  "~4.10 ...........  catattttcag  GC TGG CTA CTA 
Ile  His  Arg  G  ly  Trp  Leu  Leu 
595  596 
IV  ACT GTG AAA G  gtattgtattgg  .........  "~1.40 ..........  ctttctccttag  AG CTA TTT  CCA 
Thr  Val  Lys  G  lu  Leu  Phe  Pro 
880  881 
V  CAA GTG CTT  G  gtgagaatgacg ........  ",,0.85  .......... tttctgtttcag  GC CTC CGG TTA 
The underlined nucleotide (no. 887) surrounding the 3' boundary of intron V represents a substitution from A (cDNA) to G (gene) resulting in 
a change in the amino acid encoded from Gin to Arg (See Table 2). The underlined sequences are different from the published FcKI gene sequence 
(van de Winkel et al., 1991). The numbering of the cDNA nucleotide  sequence corresponds to FcRI cDNA Genbank accession no. M21091. 
resent inducible transcripts from F~RIa and the Fc'yRIb gene. 
The induction of Fc~RI by IFN-'y has been previously shown 
to be mediated at the level of transcription (21). In addition, 
it appears that TNF-oe alone does not have an effect on Fc3'RI 
expression  and does not augment the IFN-3,-dependent in- 
duction (Fig. 3 b). This induction occurs in the presence of 
cyclohexamide and IFN-qr but not with cyclohexamide alone, 
suggesting that de novo protein synthesis is not required and 
that it represents an immediate early response to IFN-3, (Fig. 
3 b). Once we had confirmed that induction of Fc'yRI genes 
appeared  to be IFN-3' specific, we set out to define the c/s- 
acting elements that confer IFN-'y responsiveness.  The se- 
quence of the upstream region was determined (Fig. 4) and 
the transcription start site(s) defined. We isolated RNA from 
U937 myelomonocytic  cells (before and after treatment) with 
IFN-% This mRNA was hybridized to a radiolabeled probe 
that spanned from  + 14 to  -799 bp and digested with $1 
nuclease. Three protective bands that mapped to positions 
-97,  -83, and -82 were detected upstream from the ATG 
(+1),  when mRNA from IFN-'),-treated cells was used as 
a template, but not with mRNA from untreated cells or 
tRNA (not shown). To confirm that these protective frag- 
ments corresponded to the transcription start site of Fc"/1Llb, 
a primer extension analysis was performed using an N-labeled 
oligonucleotide from + 14 to - 9 bp (not shown). Three ex- 
tended fragments that were identical to those seen in the $1 
protection assay were observed and are indicated in Fig. 4. 
It should be noted that the transcriptional start sites for the 
Fc'yRIb gene are in a similar region, but are not identical 
to those described for the Fc3,RIa gene (20, 21). Our results 
indicate that Fc3,RI  transcription can be initiated at three 
independent start sites and that there are no canonical, TATA, 
or CCAAT boxes in the 5' region flanking of the transcrip- 
tion start sites. Due to the absence of a single defined major 
transcription initiation site, the numbering of nucleotide po- 
sitions in the 5' flanking region was assigned  on the basis 
of the first nucleotide of the translation start codon as  + 1. 
Definition of  lFN-T Response  Elements.  Our next goal was 
to explore the possibility of whether the IFN-'y response ele- 
ments reside in the upstream flanking region of Fc'yR/b gene. 
The region from -689 to -7 derived from the 4.3-kb EcoRI 
genomic fragment, as described in Materials and Methods, 
was cloned into a BglII site of the promoterless CAT vector, 
pBRAMS cat I (described in Materials and Methods). When 
this construction was transfected into the human myelomono- 
cytic cell line, U937, followed by overnight treatment with 
recombinant IFN-% a 14-fold induction of CAT activity over 
background was observed  (not shown). To better define the 
gamma response region (GRR), a series of deletion construc- 
tions were prepared and defined fragments cloned into the 
pBRAMS cat I vector.  14-fold IFN-3,-inducible activity was 
observed with a fragment from  -189 to  -7.  Further dele- 
tion to bp  128, i.e.,  generating a fragment from  -128  to 
-7,  resulted in a reduction in activity to sevenfold induc- 
tion. The induction of the reported gene for both these con- 
structs was observed  only in myeloid cells and not in Hela 
cells. However, a fragment from  -79 to  -7 was not active 
in either myeloid or Hela cells, suggesting that the IFN-'y 
1118  Genomic Organization of the Putative Second Fc3,RI Gene Table  2.  Mutations  in  the Human  FcRI Gene 
Type 
Nucleotide  Amino acid 
Position  From  To  From  To 
Substitutions: 
Coding regions 
Noncoding regions 
Deletion & Insertions 
571 
cDNA 
Gene 
109  T  A 
195  T  C 
380  C  T 
706  C  T 
1  G  T 
851  G  A 
887  A  G 
1006  G  A 
1049  C  T 
1174  G  T 
1217  G  A 
1279  G  A 
Set  Thr 
Thr  Met 
Gln  Termination 
GCA GGA ATA TCT  GTC  ACT  GTG AAA 
Ala  Gly  lie  Ser  Val  Thr  Val  Lys 
GCA GGA ATA TCA CAA TAC  ACT GTG AAA 
Ala  Gly  Ile  Ser  Gln  Tyr  Thr  Val  Lys 
The nucleotides italicized and underlined in the cDNA sequence were 
found  deleted  in the gene. The nucleotides  in bold letters and underlined 
were found to be inserted in the genomic sequence. 
* Silent substitution (Ser). 
response regions resided between upstream fragment span- 
ning from  -189 to  -128 and the downstream region be- 
tween  -128  and  - 79. 
We next set out to better define the sequences  between 
-189  and  -79 that would be necessary and sufficient for 
IFN-3, responsiveness  in the context of a heterologous pro- 
moter so that we could assay expression in U937 and Hela 
cells.  Our initial attempts were complicated by the use of 
a vector containing the SV40 promoter, as this appeared  to 
silence the upstream IFN-3, response region. A construct from 
-189  to  -7 in the context of the SV40 promoter resulted 
in a fivefold induction after IFN-7 treatment. A further se- 
ries of deletion constructs in the context of the SV40 pro- 
moter suggested that sequences  contained within  -104 to 
-  78 were necessary and sufficient to account for this modest 
induction after IFN-3' treatment (results not shown). On the 
advice of Pearse et al.  (21), we refocused our attention on 
the upstream region -169 to  -128, as this region has been 
shown by this group to confer IFN-3' responsiveness  in the 
context of the basal promoter and a thymidine kinase pro- 
moter. As it appeared  that this region had been silenced in 
the context of the SV40 promoter, we prepared a construct 
containing an upstream sequence  from  -169  to  -128  in 
pBRAMS cat 2 vector that contains the heterologous thymi- 
dine kinase promoter. We were not able to detect a 10-fold 
induction in reporter gene activity in U937 cells after IFN-~/ 
treatment. 
In our earlier studies we had noted a motif RGAAAAG 
that resembles a general IFN responsive element, RGAAACG 
(24),  in both the  -104 to  -78 as well as immediately up- 
stream from -169. We therefore prepared a construct from 
-189  to  -119 (nine extra downstream bases were included 
to maintain the correct context) in pBRAMS cat 2, and found 
that this construct induced 20-50-fold induction of CAT ac- 
tivity after treatment with IFN-3, of both Hela and U937 
cells. These results suggested that this upstream region was 
necessary and sufficient to account for IFN-y responsiveness 
and, while the downstream region was active out of context, 
it probably is not physiologically  relevant as inclusion of this 
region does not confer additional activity. 
To better define basal promoter activity, we next prepared 
a construct in which - 189 to - 119, i.e., the IFN-3, response 
region was inserted into the promoterless CAT vector,  and 
recombinant plasmid was transfected into U937 and Hda cells. 
The results indicate that no inducible activity was observed, 
suggesting that the basal mydoid promoter most likely re- 
sides between  - 119 and - 7 (Fig. 5 A). It should be noted 
that when the same upstream fragment was placed in the 
context of the heterologous TK promoter, maximum IFN- 
3~-inducible activity was observed in both U937  and Hela 
cells (Fig. 5 B). Of note is that the region containing sequences 
from - 128 to - 7 resulted in a sevenfold induction after treat- 
ment ofU937 cells with IFN-3, but not Hda cells. However, 
when this region was placed in the context of the heterolo- 
gous TK promoter, it was active in both mydoid and Hela 
cells. These results suggest that the basal mydoid promoter 
resides in the region from -128 to  -7. Careful scrutiny of 
this region revealed that there is a 16-bp region that is pre- 
cisely conserved in  the  5'  upstream  region of the mouse 
,Fcq,  RIII gene (Fig.  6, A  and B) as well as a potential Pu 
box motif. The presence of a putative Pu box (Fig. 6) is rele- 
vant as its recognition site for the Pu.1 protein, a transcrip- 
tional activator expressed in macrophages B cells (25). From 
these findings, we have designated this region the "PIE re- 
gion" for Pu.1 and IFN-y elements spanning -104 to  -84. 
Discuss/on 
Treatment of mydoid cells with IFN-~ results in activa- 
tion of effector mechanisms that include upregulation of re- 
spiratory burst activity and 20-fold induction of Fc'ytkI ex- 
pression  (reviewed  in reference  18). The  study of Fc3,RI 
expression therefore provides an opportunity to explore cis- 
acting dements that confer baseline mydoid specificity as well 
as induction by IFN-3'. In this report we have characterized 
the gene structure of a second FcyRIb gene that predicts a 
soluble form of the receptor.  We have also defined c/s-acting 
elements that appear to be necessary and sufficient for IFN-3' 
responsiveness. Not surprisingly, these c/s-acting elements most 
likely serve as recognition sites for several nuclear proteins 
whose interactions are probably critical in baseline mydoid 
1119  Benech  et al. goattcatcctagtttccatttagctctctttctctcttaccacaatacctaaaaatctttttatggggttacaact 
ctgtctcaggagccacctcagtttggtggcacagagctccccacttgtactctgaaactcttttcttgaagatattg 
ttatccatgtgcatgagttatttttcttctccatagcatccacattaaacaattaattaccttggatttagccaaaa 
taaacactccaaattcatgatgtctttcaggaagagagtttgttttcttttttaaccaaaatgggagattgatcctg 
tctgtgtcccctagaggagcagaggctggtttgtattagggcagctcttgtagatgagtaacttttcccatggcctc 
atagaggctgatatagatacttctggattcaaatgattgtttggaggcattagcaggcattgaaccaattataaaga 
gtgaggttttgccatattctaaccgtaagaaacagaaacggtagagggtaaaaatagaatagaatgtcaacacaact 
ttagccttttccctggattctgagagttcataacctgaaaatcagagattcaaactgggagagatgggctaacaggt 
atgacatgggaaaagcatgtttcaaggatttgagatgtatttccccccagaaaaggaacatgatgaaaatggtcaga 
aaagg••atttc•TT••T•TTTT•TAATTTfiG•T•Tfi•AG••AC•AG•AGAA••T•TT•AATAT•TTG•ATfiTTA•A 
GATTTCACTfiCTCCCACCAGCTTGGAGACAACATGTGGTTCTTGACAACTCTfiCTCCTTTGGGgtaagttggactca 
gaggggacagttagaagggtacaggctgtggctgttgtgagtcaagagtttgtctc  ..............  C4SObp) 
..................  gatctcttgcagTTCCAGTTGATGGGCAAGTGGgtgagtgatctctaactcagcttctc 
cttctatnccactttcctacttccaaaggatgggtcctattaacctgcagaagagcatatagagaaagcagagaaag 
aagaaagatttataaattatgtaaaatctcccatattcagagcatgattttcataaaaactatgatttgtaggcttt 
ctttctaaagtttt  .................  C850bp)  ....................  tcccctttactccacttga 
tctttttctttttcttcttgtaatctccaagtagACACCACAAAGGCAfiTGATCACTTTGCAGCCTCCATGfiGTCAG 
CGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTC 
TCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAfiTfiGTGAATAC 
AGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATCCACAGAGgLaaLtatgacLLggacca 
ggagggccggaaactacaaggtcttcctctgcgttctctcctttctggatgccagatgtgtgtgtgtgtcgatttat 
ctgggtgcaggtctcagcactatctacctaccaggtgaaactaaatcagtatactc  ..................... 
....  C4100bp)  ....................  cgtatacatacattttgggttcatatttttcagGCTGGCTACTAC 
TGCAGGTCTCCAGCAGAGTCTTCATGGAAGGAGAACCTCTGGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTG 
TACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAAC 
CAACATAAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGAATATCACAAT 
ACACTGTGAAAGgtattgtattggaatagtcatagaactgatagtccctccccctgaggaccatcataaatattcta 
aactcctcactttaatttacaagtgaacaaactgg  ...........  C1400bp)  ...........  caggtttcccaa 
gggggtaaagggcatgtcttttgtgaaaaggacctggatgctaaacaggcaaccctgtcccccatcaactttctcct 
tagAGCTATTTCCAGCTCCA~TGCTGAAT~CATCT~T~ACATCCCCAETCCTG~AG~6~AATCT~GTCACCCT~AGC 
TGTGAAACAAAGTTGCTCTTGCAGAGGCCTGGTTTG~AGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCG 
AGGCAGGAACACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGCGAGGCTG 
CCACAGAGGATGGAAATGTCCTTAAGCACAGCCCTGAGTTGGAGCTTCAAGTGCTTGgtgagoatgacgggaagCCa 
ctggcacagaagaagggactcccttatctcccatgggactgaggtttgttcaaggg  ..................... 
(850bp)  ...........  tctggtctctaaatagtatctcttctctttgtctttttctgtttcagfiCCTCC~6TTAC 
CAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGAATAATfiTTTTTAGTGAACACTGTTCTCTGGGTG 
ACAATACGTAAAGAACTGAAAAGAAAGAAAAAGTGGAATTTAGAAATCTCTTTfiGATTCTGGTCATGAGAAGAA6fiT 
AATTTCCAfiCCTTCAAGAAGACAGACATTTAGAAfiAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAGCTGCAGG 
AAGGGGTGCACCGGAAGGAGCCCCAGfifiGGCCACGTAGCAGCGGCTCAGTTGGTGGCCATCGATCTGGACCGTCCCC 
TfiCCCACTTGCTCCCCATGAfiCACTGCGTACAAACATCCAAAAGTTCAACAACACCAGAACTGTGTGTCTCATGGTA 
TATAACTCTTAAAGCAAATAAATGAACTGACTTCaactgggatacatttggaootgtggtcatcaaagatgacttga 
aatgaggcctactctaaagoattcgagctc 
Figure 2.  Nucleotide sequence of the Fc~RIb gene se- 
quence. ~ons are in upper case and partial  intron sequences 
are in lower case. The underlined  nucleotides  represent 
substitutions,  whereas italicized and underlined sequences 
represent insertions. The mutated HindlII site in the second 
intron is double underlined. 
expression as well as IFN-y-indudble expression of the Fc3,gI 
gene family. 
Initially, Fc~RI was defined by several mAbs and, subse- 
quently, three homologous cDNAs have been characterized. 
The ectodomain of each eDNA, designated p130, p98/X2, 
and p90, all predict proteins with a third extracellular Ig do- 
main, a unique feature of Fc'yRI (19). Several  polymorphisms 
were featured in the original report of these cDNAs in which 
the p90/p130 transcripts were thought to be dominant. The 
Figure 3.  Northern blot analysis of mRNA derived from U937 cells. 
(a) NI indicates no induction. 1,000  U  IFN-c~ treatment  for 4 h. 300 U 
IFN-3' treatment for 4 h was sufEcient to induce two specific EcTRI tran- 
scripts of t.7 and 1.2 kb, respectively. (b) Indicates that induction of stable 
Fc"/KI mRNA transcripts is IPN-'y  dependent  and does not occur after 
treatment with recombinant  TNF. TNF does not alter IFN-3t-dependent 
induction. Cyclohexamide treatment does not superinduce mRNA tran- 
scripts  nor  does  it blunt IFN-',/inducibility. 
￿9  e o o  GAATTCATCCTAGTTTCCATTTAGCTCTCTTTCTCTCTTACCACAAT 
- 7 s ~ ACCTAAAAATCTTTTTATGGGGTTACAACTCTGTCTCAGGAGCCAC 
￿9  7 o 4  CTCAGTTTGGTGGCACAGAGCTCCCCACTTGTACTCTGAAACTCTTT 
-.5o  TCTTGAAG ATATTGTTATCCATGTGCATG  AGTTATTTTTCTTCTCC  A 
￿9  s ~ 3  TAG CATCCACATTAAACAATTAATTACCTTGGATTTAGCCAAAAT 
- s 68 AAACACTCCAAATTCATG  ATGTCTTTCAGGAAGAGAGTTTGTTTTC 
- s 22 TTTTTTAACCAAAATGGGAGATTG  ATCCTGTCTGTGTCCCCTAGAG 
- 47 o GAGCAGAGGCTGGTTTGTATTAGGGCAGCTCTTGTAGATGAGTAAC 
- 43 o TTTTCCCATGGCCTCATAGAGGCTGATATAGATACTTCTGGATTCA 
-ss4  AATGATTGTTTG  GAGGCATTAGCAGGCATTGAACCAATTATAAAG 
- 3 ￿9  s  AGTGAGGTTTTGCCATATTCTAACCGTAAGAAACAGAAACGGTAG 
-29,  AGGGTAAAAATAG  AATAGAATGTCAACACAACTTTAGCCTTTTCC 
-2~2 
.24o  CTGGATTCTGAGAGTTCATAACCTGAAAATCAGAGATTCAAACTGG 
+189  -169 
I  I 
￿9  20 a OAGAGATGGGCTAACAGGTATGAGCATGGGAAAAGCATGTTTCAA 
128  -119  /  ! 
-1 se  GGATTTGAGATGTATTTCCCAGAAAAGGAA~ATGATGAA~ATGGT 
- ~ ~  3  CAGAAAAGGCAATTTCCTTCCTCTTTTCTAATTTGGCTCTGGAGCCA 
-~s  CCAGCAGAACCTCTTCAATATCTTGCATGTTACAGATTTCACTGCTC 
-~  |§ 
￿9  ~ g  CCACCAGC'I-rGGAGACAAC  ATG  TGG  TTC TTG  ACA ACT CTG  CTC 
Figure 4.  Upstream  region of F~Rlb gene. FiUed  arrows indicate  tran- 
scription start sites as determined  by primer  extension  and $1  nuclease 
analysis.  + 1 designates the translation start site, and the beginning of the 
open reading  frame is underlined. 
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Figure 5.  CAT analysis data of the Fc'rRI 
gene promoter/enhancer region. The fold in- 
crease in CAT gene expression after 12 h of 
stimulation with 300 U/ml of human recom- 
binant IFN-y is shown for the particular cell 
line transfected. The arrows indicate potential 
transcription initiation sites in the relevant  con- 
structs. 
p98/X2  transcript  has complex direct  repeats in  the  3'  re- 
gion leading to speculation that this may represent a cDNA 
cloning artifact. The pg0/p130 share identity up to the 19th 
amino acid of the cytoplasmic tail and thereafter diverge (19). 
The p90 transcripts  predict  another  12  amino  acids  vs.  42 
extra amino acids in p130. This difference may he accounted 
for by alternative  splicing and there appears to be a cryptic 
splice donor  site at the point  where  the sequences  diverge. 
The presence of multiple differences in the three transcripts 
isolated from the same patient led Allen and Seed (19) to raise 
the possibility for another FcyRI gene.  Van der Winkel  et 
al.  (20)  have provided very compelling evidence to support 
this conclusion based on a Southern blot analysis of genomic 
DNA from three randomly selected individuals. These results 
suggested  the  existence of a  second Fc~/RI gene that lacks 
one  of the  two  internal  HindlII  sites.  The  gene  structure 
represents  this  second  gene in  that  we  show  that  the  lack 
of the HindlII site is a result of a point mutation in the second 
intron (Fig. 2), as well as several other differences in the exon 
sequence. Our genomic analysis predicts insertion of an extra 
amino acid in exon 2 as a result ofa GT deletion and ACAATA 
insertion  (Table 2)  in  the  genomic sequence,  and  therefore 
predicts a  protein  sequence of SQYTV  genomic vs.  SVTV 
Figure 6.  Sequence of promoter/enhancer region of the Fc'),ILI  gene. 
(.4) The gamma response region (GRR) and the PIE region are identified 
within the open boxes. The putative sequence  that appears  to confer IFN~ 
responsiveness is shown within the lightly stippled box, and its relation- 
ship to the X-box consensus motif of the class II MHC enhancer is shown 
(nonhomologous  nucleotides  are underlined). The potential Pu-box is shown 
within the darkly stippled box in the PIE region. The bent arrows at - 82, 
-83, and -97 indicate transcription initiation sites. A 14-bp  palindromic 
sequence (-80 to -67) that closely  resembles  the "initiator" (I~) sequence 
present in the TdT, adeno-associated  virus type d P5 promoter, and the 
human leukocyte IFN gene promoter is shown within incomplete boxes. 
A degenerate consensus sequence of the IFNw dement is shown at the 
bottom of the figure. (B) Homology  between the human F~RI promoter 
region with the 5' flanking region of the marine ~ Fc3,RIII gene. The 
PIE region of the human  Fc3~RI promoter is bracketed. 
I121  Benech  et al. for the eDNA.  At position 706, a C  to T  change predicts 
a termination  codon and therefore predicts a soluble form 
of the receptor. Northern blot analysis revealed  two IFN-3`- 
inducible transcripts  (Fig.  3),  further  supporting  the exis- 
tence of the alternative form of the gene. Several differences 
in nudeotide sequence of the Fc3`RIb gene and the p130 cDNA 
have been highlighted in Table 2. It seems likely that the diver- 
sity in the coding and the noncoding region represents differ- 
ences between two highly homologous genes as well as poly- 
morphism within these genes. In fact, recent findings by Ernst 
et al. (26) confirm the existence of this Fc3`RIb and describe 
the presence of a third Fc3`RI gene. It therefore appears that 
FcyPd, like the other Fc receptors,  is part of a multi-gene 
family. The characterization of a soluble form of Fc3`tLIb, its 
gene product, and its physiology role remain to be determined. 
Our results indicate that  sequences contained in the re- 
gion from - 189 to -  119 are necessary and sui~cient to confer 
IFN-3` responsiveness.  Pearse et al. (21) have illustrated in the 
Fc3`KIa  gene,  promoter  sequences from  -169  to  -128  as 
the GRK and have highlighted  homologues with elements 
that are represented in the promoters of MHC class II genes 
that  appear necessary for basal expression as well as IFN-3` 
responsiveness. These c/s-acting elements include X, H  and 
3'-IRE box motifs (17),  and their precise role in mediating 
IFN-3' responsiveness in the context of the Fc3'RI genes re- 
mains to be determined, especially as our results indicate that 
the FeTKI gene family response to IFN-3` is cycloheximide 
insensitive (Fig. 3), whereas the IFN-3`-dependent upregula- 
tion of MHC class II genes requires new protein synthesis 
(17).  Our results indicate the importance of another motif, 
RGAAAAG,  that  is represented in upstream  region  -189 
to  - 169 and in downstream region  -  113 to  -  104, and - 95 
to  -84,  and its inclusion confers enhanced IFN-3` respon- 
siveness  (Fig,  6 A).  Of interest is that  this motif is similar 
to a general IFN response element, GAAACG, which is found 
in the promoters of IFN-responsive genes and appears as a 
c/s-acting  element of HSV immediate early genes (24).  It is 
interesting to note that IFN-c~ treatment impeded transcrip- 
tion of HSV-1 IE genes, and we postulate that the squelching 
effects observed after IFN-3` treatment,  which we observed 
in the context of the SV40 promoter, may occur by a similar 
mechanism. 
It is likely that myeloid specificity is determined in large 
part by the basal promoter.  In this regard,  it is important 
to note that in the absence of a heterologous promoter, both 
the GRR and PIE regions function only in myeloid cells. 
The identification of a potential Pu box is relevant, as Pu.1 
proteins appear to be important partly in determining myeloid- 
specific gene expression (25). The absence of canonical TATA 
and CAT boxes led us to define a 14-bp palindromic sequence 
beginning at position  - 80, 2 bp downstream from the most 
3'  transcription  start  site  (Fig.  6).  The  sequences  closely 
resembles the initiator sequence that appears to be both neces- 
sary and su~dent for basal transcription of the terminal deoxy- 
nucleotidyl transferase  gene (27), adeno-associated virus type 
2  P5 promoter  (28),  and  the  human  leukocyte IFN  gene 
(hLelF) (29). The initiator sequence in these genes has been 
shown to mediate transcription by binding to the YY1 pro- 
tein, which appears to direct the transcription machinery in 
the absence of TATA elements (30, 31). The importance of 
the initiator element in basal and tissue-specific transcription 
of the Fc3,RI gene remains an open and interesting question. 
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